SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub: REGAL, GPS, SLS009, AML Catalysts and the July 2026 CEO Communication Update

SELLAS CEO Angelos Stergiou used a new LinkedIn post to push back against recent criticism of the REGAL Phase 3 trial, explain why the company should not stop at 78 events, and prepare investors for an official quiet period once the 80th event is announced. The post is sentiment-relevant, but it is not a topline-data release and does not confirm that the 80th event has already occurred.